Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
20-Aug-2020
Kazia's paxalisib granted Fast Track Designation by FDA
19-Aug-2020
Change in substantial holding
14-Aug-2020
Change in substantial holding
7-Aug-2020
Kazia's paxalisib obtains Rare Pediatric Disease Designation
31-Jul-2020
Appendix 4C - quarterly
27-Jul-2020
Change in substantial holding
20-Jul-2020
Ceasing to be a substantial holder
25-Jun-2020
Kazia presents to Hidden Gems ShareCafe Investor Webinar
19-Jun-2020
Change in substantial holding
16-Jun-2020
Kazia presentation to TKIRW
Previous
1
2
3
4
5
6
7
8
9
10
11
Next
